Second Genome Announces New SVP of Corporate Development
November 30, 2011, San Bruno, CASecond Genome welcomes Mohan S. Iyer to the team. As SVP of Corporate Development, Mohan is responsible for building relationships and working with our partners, including biopharma and nutrition companies, to identify novel biomarkers for classifying patient populations and to assess the impact of novel microbiome-modulating products.
Second Genome Announces Series A Financing
August 9, 2011, San Francisco, CASecond Genome, Inc., the microbiome company, announced today that it has closed a Series A investment co-led by new investors Advanced Technology Ventures (ATV) and Morgenthaler Ventures, and including previous investors Wavepoint Ventures, Seraph Group, and individual Series Seed investors. Second Genome will use the $5 million investment to further its development of microbiome-based personalized medicine solutions for gastrointestinal diseases and disorders.